Radiopharm Theranostics Ltd (RADX) Form 424B3 — Sep 23, 2026
Radiopharm Theranostics filed a 424B3 prospectus registering the resale of up to 1,345,728 ADSs, representing 403,718,400 ordinary shares, issuable upon exercise of warrants held by Selling Shareholders from its July 2026 private placement. The company receives no proceeds from these shareholder sales, though it could receive up to approximately US$5.1 million if the warrants (exercise price US$3.79/US$3.95 per ADS, expiring July 31, 2029) are exercised. The July 2026 placement itself raised approximately US$3.3 million, with an additional A$6.7 million from an Australian placement.
Key figures
- Gross Proceeds
- US$3.3 million (July 2026 Private Placement proceeds to company)
- Shares Offered
- 1,345,728 ADSs (403,718,400 ordinary shares)
- Shares Outstanding
- 4337549491
- Warrant expiry
- July 31, 2029
- Ordinary shares per ads
- 300
- Private placement proceeds usd
- US$3.3 million
- Warrant exercise potential usd
- up to approximately US$5.1 million
- Investor warrant exercise price
- US$3.79 per ADS (1,281,646 ADSs)
- Cash and equivalents dec31 2025 AUD
- A$34,515,397 thousand actual basis (in thousands per filing table)
- Placement agent warrant exercise price
- US$3.95 per ADS (64,082 ADSs)
- Australian placement gross proceeds aud
- A$6.7 million
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.